Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Therapeutic Innovation & Regulatory Science|September 19, 2018
Reporting Adverse Drug Reactions in Product LabelsBrenda Crowe, Christy Chuang-Stein, Sally Lettis, et al.
The Lancet. Respiratory Medicine|July 28, 2016
Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysisIan D Pavord, Sally Lettis, Antonio Anzueto, et al.
Respiratory Research|August 25, 2019
Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary diseaseSteven J Pascoe, Alberto Papi, Dawn Midwinter, et al.
The European Respiratory Journal|February 27, 2016
Blood eosinophils as a marker of response to inhaled corticosteroids in COPDNeil C Barnes, Raj Sharma, Sally Lettis, et al.
BMJ Open Respiratory Research|September 22, 2016
Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPDJames L Kreindler, Michael L Watkins, Sally Lettis, et al.
Pharmaceutical Statistics|January 8, 2022
Estimation of a treatment policy estimand for time to event data using data collected post discontinuation of randomised treatmentBenjamin Hartley, Thomas Drury, Sally Lettis, et al.
Respiratory Research|January 8, 2020
Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysisBenjamin F Hartley, Neil C Barnes, Sally Lettis, et al.
Respiratory Medicine|May 5, 2018
Blood eosinophil levels as a biomarker in COPDGuy Brusselle, Ian D Pavord, Sarah Landis, et al.
Respiratory Research|April 8, 2015
Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacyGillian Stynes, Henrik Svedsater, Jaro Wex, et al.
Thorax|November 21, 2015
Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPDIan D Pavord, Sally Lettis, Nicholas Locantore, et al.
Pageof 3